About Domainex
Domainex is a company based in Cambridge (United Kingdom) founded in 2001. Domainex has raised $4.97 million across 6 funding rounds from investors including YFM Equity Partners, Wellcome and Longbow Capital. The company has 93 employees as of January 31, 2022. Domainex offers products and services including Integrated Drug Discovery Services, Medicinal Chemistry, Structural Biology, and Assay Development. Domainex operates in a competitive market with competitors including Evotec, Crown Bioscience, Alloy Therapeutics, NIH and Viva Biotech, among others.
- Headquarter Cambridge, United Kingdom
- Employees 93 as on 31 Jan, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Domainex Limited
- Date of Incorporation 10 Dec, 2001
- Jurisdiction SAFFRON WALDEN, ENGLAND
-
Annual Revenue
$15.49 M (USD)19as on Dec 31, 2022
-
Net Profit
$1.85 M (USD)8as on Dec 31, 2022
-
EBITDA
Not available
-
Total Equity Funding
$4.97 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
YFM Equity Partners
& 4 more
-
Employee Count
93
as on Jan 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Domainex
Domainex offers a comprehensive portfolio of products and services, including Integrated Drug Discovery Services, Medicinal Chemistry, Structural Biology, and Assay Development.
Comprehensive platform for hit to lead optimization in pharmaceuticals
Design and synthesis of compounds for drug development
Techniques like X-ray crystallography for protein analysis
Creation of tests for evaluating drug candidates
People of Domainex
Unlock access to complete
Unlock access to complete
Funding Insights of Domainex
Domainex has successfully raised a total of $4.97M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Domainex
Domainex has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include YFM Equity Partners, Wellcome and Longbow Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Domainex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Domainex
Investment portfolio details for Domainex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Domainex
Detailed financials for Domainex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Domainex Comparisons
Peer comparison for Domainex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Domainex
Domainex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Crown Bioscience, Alloy Therapeutics, NIH and Viva Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services are provided to biopharma sector.
|
|
| Locked | Locked | Locked |
Cancer and CVMD drugs are developed using PDX models.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided for therapeutic development.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery and development research services are provided.
|
Detailed competitors of Domainex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Domainex
Complete news archive for Domainex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Domainex
Domainex was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Domainex is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Domainex is a funded company, having raised a total of $4.97M across 6 funding rounds to date.
As of Jan 31, 2022, the latest employee count at Domainex is 93.
Annual revenue of Domainex is $15.49M as on Dec 31, 2022.
Domainex is a drug discovery CRO that develops small molecule compounds for epigenetic research and inflammatory diseases. Domainexs services include proprietary platforms based services such as Combinatorial Domain Hunting (for structural studies and assay development) and LeadBuilder (virtual and fragment-based approaches to hit identification), medicinal chemistry and computational chemistry services, protein expression capabilities and cell-based and biochemical assay development offering. The company had won the 1.4m Biomedical Catalyst Award for the success of its Lead Compound in Pre-clinical Model of COPD. Domainex merged with NCE Discovery in 2007 to form a drug discovery company focussed on nucleotide triphosphate (NTP)-dependent proteins. The companys clientele includes UCB, FORMA Therapeutics, St Georges University, The Institute of Cancer Research and Auspherix. Domainex claims that it has delivered on an average one candidate drug per year in the six years since 2010.
Domainex's top competitors include Evotec, Crown Bioscience and NIH.
Domainex offers Integrated Drug Discovery Services, Medicinal Chemistry, Structural Biology, and Assay Development.
Domainex has 5 investors. Key investors include YFM Equity Partners, Wellcome, Longbow Capital, Bury Fitzwilliam-Lay And Partners, and Takeda Ventures.